Inimmune Corp 2024 Immunotherapy Corporate Presentation

Inimmune is a clinical-stage immunotherapy company developing disease-modifying therapies targeting the innate immune system across vaccine adjuvants, autoimmune diseases, infectious diseases, oncology, and allergies. The deck highlights recent milestones including Phase 1 allergy studies with INI-2004 and ongoing Phase 1 oncology trials with INI-4001, plus a global commercialization partnership with SPI Pharma for proprietary vaccine adjuvant systems.